Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Janet Snell-Bergeon to Blood Glucose

This is a "connection" page, showing publications Janet Snell-Bergeon has written about Blood Glucose.

 
Connection Strength
 
 
 
4.815
 
  1. Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 06; 26(6):367-374.
    View in: PubMed
    Score: 0.402
  2. Polsky S, Buschur E, Dungan K, Garcetti R, Nease E, Malecha E, Bartholomew A, Johnson C, Pyle L, Snell-Bergeon J. Randomized Trial of Assisted Hybrid Closed-Loop Therapy Versus Sensor-Augmented Pump Therapy in Pregnancy. Diabetes Technol Ther. 2024 08; 26(8):547-555.
    View in: PubMed
    Score: 0.399
  3. Polsky S, Garcetti R, Pyle L, Joshee P, Demmitt JK, Snell-Bergeon JK. Continuous Glucose Monitor Use With Remote Monitoring Reduces Fear of Hypoglycemia in Pregnant Women With Type 1 Diabetes: A Pilot Study. J Diabetes Sci Technol. 2020 01; 14(1):191-192.
    View in: PubMed
    Score: 0.296
  4. Basu A, Alman AC, Snell-Bergeon JK. Dietary fiber intake and glycemic control: coronary artery calcification in type 1 diabetes (CACTI) study. Nutr J. 2019 04 03; 18(1):23.
    View in: PubMed
    Score: 0.283
  5. Shah VN, Gallo TL, Marker M, Snell-Bergeon JK. Glycemic Control With Early Initiation of Continuous Glucose Monitoring System in Adults With Recently Diagnosed Type 1A Diabetes. J Diabetes Sci Technol. 2018 01; 12(1):228-229.
    View in: PubMed
    Score: 0.251
  6. Maahs DM, Chase HP, Westfall E, Slover R, Huang S, Shin JJ, Kaufman FR, Pyle L, Snell-Bergeon JK. The effects of lowering nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin A1c levels in type 1 diabetes. Diabetes Technol Ther. 2014 May; 16(5):284-91.
    View in: PubMed
    Score: 0.198
  7. Snell-Bergeon JK, Roman R, Rodbard D, Garg S, Maahs DM, Schauer IE, Bergman BC, Kinney GL, Rewers M. Glycaemic variability is associated with coronary artery calcium in men with Type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. Diabet Med. 2010 Dec; 27(12):1436-42.
    View in: PubMed
    Score: 0.159
  8. Hirsch IB, Garg SK, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes. JAMA Netw Open. 2025 10 01; 8(10):e2539278.
    View in: PubMed
    Score: 0.111
  9. Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.
    View in: PubMed
    Score: 0.109
  10. Garg SK, Kaur G, Renner D, Lanning MS, Mason E, Beatson C, Ciesco K, Snell-Bergeon J. Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther. 2025 03; 27(3):152-160.
    View in: PubMed
    Score: 0.107
  11. Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 01; 27(1):1-9.
    View in: PubMed
    Score: 0.106
  12. DiStefano MJ, McQueen RB, Gao V, Klein MP, Snell-Bergeon JK, Polsky S. The Cost of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 1 Diabetes Pregnancies in the United States: A Cost-Consequences Analysis Using Real-World Evidence. Diabetes Technol Ther. 2025 04; 27(4):329-333.
    View in: PubMed
    Score: 0.105
  13. Karakus KE, Snell-Bergeon J, Mason E, Akturk HK. Improvement in Newly Defined Continuous Glucose Monitor Metrics, Extended Hypoglycemia, and Extended Hyperglycemia With Automated Insulin Delivery Initiation in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 May; 20(3):721-726.
    View in: PubMed
    Score: 0.105
  14. Karakus KE, Snell-Bergeon JK, Akturk HK. Comparison of Computational Statistical Packages for the Analysis of Continuous Glucose Monitoring Data with a Reference Software, "Ambulatory Glucose Profile," in Type 1 Diabetes. Diabetes Technol Ther. 2025 03; 27(3):202-208.
    View in: PubMed
    Score: 0.104
  15. Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. 2024 11; 26(11):5202-5210.
    View in: PubMed
    Score: 0.103
  16. King J, Buschur E, Snell-Bergeon J, Pyle L, Dungan K, Garcetti R, Nease E, Bartholomew A, Johnson C, Polsky S. Glycemic Variability in Pregnant Individuals Using Assisted Hybrid Closed-Loop Therapy Versus Sensor-Augmented Pump Therapy. J Diabetes Sci Technol. 2024 09; 18(5):1260-1262.
    View in: PubMed
    Score: 0.102
  17. Gao V, Snell-Bergeon JK, Malecha E, Johnson CA, Polsky S. Clinical Effectiveness of Continuous Glucose Monitoring in Pregnancies Affected by Type 1 Diabetes. Diabetes Technol Ther. 2024 08; 26(8):526-535.
    View in: PubMed
    Score: 0.100
  18. Shah VN, Kanapka LG, Akturk HK, Polsky S, Forlenza GP, Kollman C, Beck RW, Snell-Bergeon JK. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study. Diabetes Technol Ther. 2024 04; 26(4):246-251.
    View in: PubMed
    Score: 0.099
  19. Basu A, Hooyman A, Richardson LA, Alman AC, Snell-Bergeon JK. Longitudinal Associations of Dietary Fiber Intake with Glycated Hemoglobin and Estimated Insulin Sensitivity in Adults with and without Type 1 Diabetes. Nutrients. 2023 Oct 31; 15(21).
    View in: PubMed
    Score: 0.097
  20. Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022 03 01; 45(3):750-753.
    View in: PubMed
    Score: 0.087
  21. Sklar J, Pyle L, Snell-Bergeon JK, Garcetti R, Joshee P, Demmitt JK, Polsky S. Glycemic variability and indices of glycemic control among pregnant women with type 1 diabetes (T1D) based on the use of continuous glucose monitoring share technology. J Matern Fetal Neonatal Med. 2022 Dec; 35(25):8968-8974.
    View in: PubMed
    Score: 0.085
  22. Shah VN, Akturk HK, Joseph H, Schneider N, Snell-Bergeon JK. A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec. Diabetes Obes Metab. 2021 08; 23(8):1936-1941.
    View in: PubMed
    Score: 0.083
  23. Levin P, Hoogwerf BJ, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus. Endocr Pract. 2021 May; 27(5):449-454.
    View in: PubMed
    Score: 0.080
  24. Polsky S, Garcetti R, Pyle L, Joshee P, Demmitt JK, Snell-Bergeon JK. Continuous glucose monitor use with and without remote monitoring in pregnant women with type 1 diabetes: A pilot study. PLoS One. 2020; 15(4):e0230476.
    View in: PubMed
    Score: 0.076
  25. Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020 04; 22(4):583-589.
    View in: PubMed
    Score: 0.075
  26. Vigers T, Chan CL, Snell-Bergeon J, Bjornstad P, Zeitler PS, Forlenza G, Pyle L. cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data. PLoS One. 2019; 14(10):e0216851.
    View in: PubMed
    Score: 0.073
  27. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. Diabetes Technol Ther. 2019 01; 21(1):6-10.
    View in: PubMed
    Score: 0.069
  28. Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
    View in: PubMed
    Score: 0.068
  29. Alman AC, Smith SR, Eckel RH, Hokanson JE, Burkhardt BR, Sudini PR, Wu Y, Schauer IE, Pereira RI, Snell-Bergeon JK. The ratio of pericardial to subcutaneous adipose tissues is associated with insulin resistance. Obesity (Silver Spring). 2017 07; 25(7):1284-1291.
    View in: PubMed
    Score: 0.062
  30. Bjornstad P, McQueen RB, Snell-Bergeon JK, Cherney D, Pyle L, Perkins B, Rewers M, Maahs DM. Fasting blood glucose--a missing variable for GFR-estimation in type 1 diabetes? PLoS One. 2014; 9(4):e96264.
    View in: PubMed
    Score: 0.050
  31. Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013 Jan-Feb; 19(1):19-28.
    View in: PubMed
    Score: 0.046
  32. Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther. 2012 Jun; 14 Suppl 1:S51-8.
    View in: PubMed
    Score: 0.044
  33. Snell-Bergeon JK, Nadeau K. Cardiovascular disease risk in young people with type 1 diabetes. J Cardiovasc Transl Res. 2012 Aug; 5(4):446-62.
    View in: PubMed
    Score: 0.044
  34. Bergman BC, Howard D, Schauer IE, Maahs DM, Snell-Bergeon JK, Eckel RH, Perreault L, Rewers M. Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes. J Clin Endocrinol Metab. 2012 May; 97(5):1663-72.
    View in: PubMed
    Score: 0.043
  35. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011 Oct; 28(10):1176-81.
    View in: PubMed
    Score: 0.042
  36. Maahs DM, Ogden LG, Dabelea D, Snell-Bergeon JK, Daniels SR, Hamman RF, Rewers M. Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia. 2010 Dec; 53(12):2518-25.
    View in: PubMed
    Score: 0.039
  37. King J, Buschur E, Garcetti R, Pyle L, Sakamoto C, Snell-Bergeon J, Nease E, Bartholomew A, Dungan K, Polsky S. Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy. J Diabetes Complications. 2025 04; 39(4):109000.
    View in: PubMed
    Score: 0.027
  38. Brigham TL, Klein MP, Snell-Bergeon JK, Polsky S. Case series of a hybrid closed loop therapy system used in pregnancy. Acta Diabetol. 2025 Sep; 62(9):1439-1449.
    View in: PubMed
    Score: 0.027
  39. Buschur EO, Reedy J, Berget C, Barnard JG, Garcetti R, Nease E, Bartholomew A, Johnson C, Driscoll KA, Dungan KM, Snell-Bergeon JK, Pyle LL, Polsky S. Mixed Methods Randomized Controlled Trial Comparing Quality of Life for Pregnant Women With Type 1 Diabetes Using Hybrid Closed-Loop to Sensor-Augmented Pump Therapy. Endocr Pract. 2025 Apr; 31(4):494-502.
    View in: PubMed
    Score: 0.026
  40. Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.
    View in: PubMed
    Score: 0.025
  41. Trojanowski PJ, Pardon A, Reynolds C, O'Donnell HK, Alonso GT, Majidi S, Snell-Bergeon J, Wadwa RP, Driscoll KA. Body mass index moderates the association between diabetes distress and objective self-management behaviours in adolescents with type 1 diabetes and elevated A1Cs. Diabet Med. 2024 Jul; 41(7):e15325.
    View in: PubMed
    Score: 0.025
  42. Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. 2025 Mar; 19(2):292-296.
    View in: PubMed
    Score: 0.025
  43. Abushamat LA, Schauer IE, Low Wang CC, Mitchell S, Herlache L, Bridenstine M, Durbin R, Snell-Bergeon JK, Regensteiner JG, Reusch JE. Rosiglitazone improves insulin resistance but does not improve exercise capacity in individuals with impaired glucose tolerance: A randomized clinical study. J Investig Med. 2024 03; 72(3):294-304.
    View in: PubMed
    Score: 0.025
  44. Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care. 2003 Oct; 26(10):2923-8.
    View in: PubMed
    Score: 0.024
  45. Karakus KE, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. Diabetes Care. 2023 09 01; 46(9):1646-1651.
    View in: PubMed
    Score: 0.024
  46. Pauley ME, Tommerdahl KL, Snell-Bergeon JK, Forlenza GP. Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. Curr Cardiol Rep. 2022 12; 24(12):2043-2056.
    View in: PubMed
    Score: 0.023
  47. Tell SS, Schafer M, Vigers T, Baumgartner AD, Lyon E, Gross S, Polsky S, Snell-Bergeon JK, Schauer IE, Nadeau KJ. Bromocriptine quick-release as adjunct therapy in youth and adults with type 1 diabetes: A randomized, placebo-controlled crossover study. Diabetes Obes Metab. 2022 11; 24(11):2148-2158.
    View in: PubMed
    Score: 0.022
  48. Akturk HK, Snell-Bergeon J, Shah VN. Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes. Diabetes Technol Ther. 2022 10; 24(10):779-783.
    View in: PubMed
    Score: 0.022
  49. Akturk HK, Herrero P, Oliver N, Wise H, Eikermann E, Snell-Bergeon J, Shah VN. Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration. Diabetes Technol Ther. 2022 10; 24(10):749-753.
    View in: PubMed
    Score: 0.022
  50. Akturk HK, Snell-Bergeon J, Shah VN. Health Care Professionals' Perspectives on Use of Diabetes Technologies for Managing Visually Impaired Patients With Diabetes. J Diabetes Sci Technol. 2023 11; 17(6):1610-1613.
    View in: PubMed
    Score: 0.022
  51. Shah VN, Snell-Bergeon JK, Demmitt JK, Joshee P, Garcetti R, Pyle L, Polsky S. Relationship Between Time-in-Range, HbA1c, and the Glucose Management Indicator in Pregnancies Complicated by Type 1 Diabetes. Diabetes Technol Ther. 2021 12; 23(12):783-790.
    View in: PubMed
    Score: 0.021
  52. Buschur EO, Campbell K, Pyle L, Garcetti R, Joshee P, Demmitt JK, Snell-Bergeon JK, Polsky S. Exploratory Analysis of Glycemic Control and Variability Over Gestation Among Pregnant Women with Type 1 Diabetes. Diabetes Technol Ther. 2021 11; 23(11):768-772.
    View in: PubMed
    Score: 0.021
  53. Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, Driscoll KA, Forlenza GP. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab. 2021 09; 23(9):2048-2057.
    View in: PubMed
    Score: 0.021
  54. Akturk HK, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes. Diabetes Technol Ther. 2021 01; 23(1):81-83.
    View in: PubMed
    Score: 0.019
  55. Syreeni A, Sandholm N, Cao J, Toppila I, Maahs DM, Rewers MJ, Snell-Bergeon JK, Costacou T, Orchard TJ, Caramori ML, Mauer M, Klein BEK, Klein R, Valo E, Parkkonen M, Forsblom C, Harjutsalo V, Paterson AD, Groop PH. Genetic Determinants of Glycated Hemoglobin in Type 1 Diabetes. Diabetes. 2019 04; 68(4):858-867.
    View in: PubMed
    Score: 0.017
  56. Perreault L, Newsom SA, Strauss A, Kerege A, Kahn DE, Harrison KA, Snell-Bergeon JK, Nemkov T, D'Alessandro A, Jackman MR, MacLean PS, Bergman BC. Intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle. JCI Insight. 2018 02 08; 3(3).
    View in: PubMed
    Score: 0.016
  57. Combs TP, Snell-Bergeon JK, Maahs DM, Bergman BC, Lamarche M, Iberkleid L, AbdelBaky O, Tisch R, Scherer PE, Marliss EB. Adiponectin-SOGA Dissociation in Type 1 Diabetes. J Clin Endocrinol Metab. 2015 Aug; 100(8):E1065-73.
    View in: PubMed
    Score: 0.014
  58. Bjornstad P, Lanaspa MA, Ishimoto T, Kosugi T, Kume S, Jalal D, Maahs DM, Snell-Bergeon JK, Johnson RJ, Nakagawa T. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015 Sep; 58(9):1993-2002.
    View in: PubMed
    Score: 0.014
  59. Kinney GL, Snell-Bergeon JK, Maahs DM, Eckel RH, Ehrlich J, Rewers M, Hokanson JE. Lipoprotein-associated phospholipase A2 activity predicts progression of subclinical coronary atherosclerosis. Diabetes Technol Ther. 2011 Mar; 13(3):381-7.
    View in: PubMed
    Score: 0.010
  60. Garg SK, Ritchie PJ, Moser EG, Snell-Bergeon JK, Freson BJ, Hazenfield RM. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab. 2011 Feb; 13(2):137-43.
    View in: PubMed
    Score: 0.010
  61. Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, Rewers M. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes. 2011 Jan; 60(1):306-14.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)